Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-03-13Clinical Trial Update: Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer
The clinical trial assessing PD-L1 imaging with 89Zr-atezolizumab in metastatic triple-negative breast cancer has been terminated.
-
CLINICAL_TRIALS withdrawal · 2026-03-11Clinical Trial Update: A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer [Phase 1]
A Phase 1 study evaluating intratumoral influenza vaccine administration in patients with breast cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-03-05Clinical Trial Update: IL-1 Inhibition in Early TNBC [Phase 2]
A Phase 2 trial evaluating IL-1 inhibition in early-stage triple-negative breast cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-02-19Clinical Trial Update: A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) [Phase 2]
The Phase 2 trial MK-5890-003 evaluating boserolimab with pembrolizumab and chemotherapy for early triple-negative breast cancer has been wi…
-
CLINICAL_TRIALS withdrawal · 2026-02-04Clinical Trial Update: Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer [NA]
Withdrawn clinical trial evaluating a virtual mental health intervention for fear of progression in women with high-risk or stage III-IV gyn…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-12-10Clinical Trial Update: Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI). [EARLY_Phase 1]
An early-phase pilot study evaluating whether contrast-enhanced ultrasound can predict treatment response to chemotherapy plus immune checkp…
-
CLINICAL_TRIALS withdrawal · 2025-12-08Clinical Trial Update: A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer [Phase 2]
A Phase 2 window trial evaluating the immunological effects of avelumab and aspirin in triple-negative breast cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-11-21Clinical Trial Update: A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 trial evaluating BT-001 alone and in combination with pembrolizumab in metastatic or advanced solid tumors has been terminated.
-
CLINICAL_TRIALS withdrawal · 2025-09-02Clinical Trial Update: Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures [Phase 2]
Phase 2 trial targeting MDMD and PD-1 in tumors with tertiary lymphoid structures has been withdrawn; the study covered soft tissue sarcoma,…
-
CLINICAL_TRIALS withdrawal · 2025-07-16Clinical Trial Update: Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer) [EARLY_Phase 1]
An early-phase 1 trial of cyclosporin A for triple-negative breast cancer with DNA damage repair deficiency has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-07-03Clinical Trial Update: Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer [Phase 1]
A National Cancer Institute-sponsored Phase 1 trial evaluating adding ASTX660 (tolinapant) to eribulin for advanced triple-negative breast c…
-
CLINICAL_TRIALS withdrawal · 2025-07-01Clinical Trial Update: A Study to Investigate LYL797 in Adults With Solid Tumors [Phase 1]
Lyell Immunopharma's Phase 1 study of LYL797 in adults with solid tumors has been terminated.
-
CLINICAL_TRIALS withdrawal · 2025-02-21Clinical Trial Update: QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine [Phase 2]
ImmunityBio's Phase 2 trial of the NANT Neoadjuvant TNBC Vaccine for triple-negative breast cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-02-21Clinical Trial Update: QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy [Phase 1, Phase 2]
The QUILT-3.049 trial of the NANT TNBC vaccine in triple-negative breast cancer has been withdrawn, ending a Phase 1/2 combination immunothe…
-
CLINICAL_TRIALS withdrawal · 2025-01-29Clinical Trial Update: Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer [Phase 2]
Phase 2 trial evaluating a dendritic cell-based treatment combined with immunotherapy for metastatic or unresectable triple-negative breast …
-
CLINICAL_TRIALS withdrawal · 2024-12-09Clinical Trial Update: Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer [EARLY_Phase 1]
An early-phase pilot study of Glembatumumab Vedotin as neoadjuvant therapy for gp-NMB-expressing high-risk triple-negative breast cancer has…
-
CLINICAL_TRIALS withdrawal · 2024-10-24Clinical Trial Update: Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer [Phase 2]
Phase 2 trial of panitumumab and pembrolizumab in combination with neoadjuvant chemotherapy for stage III-IV triple-negative breast cancer h…
-
CLINICAL_TRIALS withdrawal · 2024-05-10Clinical Trial Update: Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study [NA]
A feasibility study evaluating hypnosis for pain in Black women with advanced breast cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-10-22Clinical Trial Update: Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer [Phase 3]
Phase 3 trial investigating enzalutamide with paclitaxel vs placebo with paclitaxel in advanced triple-negative breast cancer was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-07-18Clinical Trial Update: Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating Glembatumumab Vedotin in combination with nivolumab and ipilimumab for advanced, unresectable solid tu…
-
CLINICAL_TRIALS withdrawal · 2018-07-05Clinical Trial Update: Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC [Phase 1]
Phase 1 trial of Mirvetuximab Soravtansine (IMG853) in folate receptor alpha-expressing triple-negative breast cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-06-27Clinical Trial Update: Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors [NA]
A clinical trial evaluating immunochemotherapy with optional hypofractionated radiation for complete response in solid tumors has been withd…
-
CLINICAL_TRIALS withdrawal · 2017-04-24Clinical Trial Update: Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction [Phase 1]
A Phase 1 clinical trial of talazoparib in patients with advanced or metastatic solid tumors unsuitable for surgery and with liver or kidney…
-
CLINICAL_TRIALS withdrawal · 2017-03-09Clinical Trial Update: A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer [Phase 2]
A Phase 2 trial evaluating neoadjuvant paclitaxel in combination with bavituximab for early-stage triple-negative breast cancer has been wit…
-
CLINICAL_TRIALS withdrawal · 2016-12-07Clinical Trial Update: A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients [Phase 1, Phase 2]
This Phase 1/Phase 2 trial evaluating CDX-1401 in combination with Poly-ICLC and pembrolizumab for previously treated advanced solid tumors …